Close Menu

VA

The contract was awarded as part of the VA's Precision Oncology Program, which aims to provide advanced clinical care and generate cancer biomarker data.

The $12 million PRIME study will involve 2,000 veterans with major depressive disorder and 250 healthcare providers across 21 VA medical centers.

The company, which first signed on to provide services to the VA's Million Veteran Program in 2013, will provide the department with 34,000 more genomes.

The test analyzes clinically relevant genetic variants for 14 genes related to certain pain and mental health medication responses to help guide clinicians' prescribing decisions.

Advanced cancer patients at the VA will now have access to the company's blood-based PlasmaSelect 64 test as well as the CancerSelect 125 tissue test.

The partners have formed a public/private partnership to foster collaboration and data integration between different institutes researching brain trauma.

The VA has been steadily increasing its capacity to whole-genome sequence enrollees, and may now sequence as many as 30,000 individuals over the next two years.

The deal replaces an existing cancer testing contract to include PGDx's CancerSelect 125 test for pan-cancer tumor profiling.

VA patients will now have access to Polymedco's colorectal cancer screening products, including the Epigenomics Epi proColon.

The contract provides coverage of ConfirmMDx testing at the Medicare rate for veterans within the VA health system.

Pages

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.